Upidosin

Upidosin (Rec 15/2739) is an α-1 adrenoceptor (α-1 AR) antagonist. Upidosin shows moderate selectivity for the α-1A AR subtype. Upidosin shows uroselectivity in urethra and prostate with a Kb value of 2-3 nM higher than in ear artery and aorta with a Kb value of 20-100 nM. Upidosin inhibits [3H]prazosin binding to cloned human α-1A adrenergic receptor. Upidosin can be used for the research of urethral obstruction[1].

Product Specifications

CAS Number

[152735-23-4]

Product Name Alternative

Rec 15/2739; Recordati 15/2739; SB 216469

UNSPSC

12352005

Target

Adrenergic Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/upidosin.html

Purity

99.48

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

COC(C=CC=C1)=C1N(CC2)CCN2CCCNC(C3=C4C(C(C(C)=C(C5=CC=CC=C5)O4)=O)=CC=C3)=O

Molecular Formula

C31H33N3O4

Molecular Weight

511.61

References & Citations

[1]Leonardi A, et al. Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469) : role of the alpha-1L adrenoceptor in tissue selectivity, part I. J Pharmacol Exp Ther. 1997 Jun;281 (3) :1272-83.|[2]Testa R, et al. Functional antagonistic activity of Rec 15/2739, a novel alpha-1 antagonist selective for the lower urinary tract, on noradrenaline-induced contraction of human prostate and mesenteric artery. J Pharmacol Exp Ther. 1996 Jun;277 (3) :1237-46.|[3]Kenny BA, et al. Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol. 1996 Jun;118 (4) :871-8.